The demarcation between younger and older acute myeloid leukemia patients: A pooled analysis of 3 prospective studies (pages 3326–3333)
Masamitsu Yanada, Shigeki Ohtake, Shuichi Miyawaki, Hisashi Sakamaki, Toru Sakura, Tomoya Maeda, Koichi Miyamura, Norio Asou, Iekuni Oh, Junichi Miyatake, Hiroyuki Kanbayashi, Jin Takeuchi, Masatomo Takahashi, Nobuaki Dobashi, Hitoshi Kiyoi, Yasushi Miyazaki, Nobuhiko Emi, Yukio Kobayashi, Ryuzo Ohno and Tomoki Naoe, for the Japan Adult Leukemia Study Group
Article first published online: 24 JUN 2013 | DOI: 10.1002/cncr.28212
Data were analyzed for 2276 patients who were treated uniformly regardless of age in 3 consecutive prospective acute myeloid leukemia studies. These findings justify the use of intensive chemotherapy without dose attenuation for older but fit patients with acute myeloid leukemia, at least up to the age of 64 years.